×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

EUROTOX 2023 »áºó¾«Ñ¡ | ×ðÁú¿­Ê±ÍŶÓÓëÄú¹²¾Û¶¾Àíѧ´ó»á

2023-09-14
|
»á¼ûÁ¿£º

EUROTOX-2023-»áºó¾«Ñ¡-·âÃæ.jpg

Àú¾­ËÄÄêÆÚ´ý£¬µÚ57½ìÅ·ÖÞ¶¾Àíѧ¼ÒºÍÅ·ÖÞ¶¾Àíѧ»á´ó»á£¨57TH CONGRESS OF THE EUROPEAN SOCIETIES OF TOXICOLOGY£¬EUROTOX 2023£©ÖÕÓڻعéÏßÏ£¬ÔÚ˹ÂåÎÄÄáÑǬ²¼¶ûÑÅÄÇÈÈÁÒ¾ÙÐÐ ¡£

±¾´Î´ó»áÓÉ˹ÂåÎÄÄáÑǶ¾Àíѧ»áÖ÷Àí£¬Ö÷ÌâÊÇ£ºToxicology ¨C multidisciplinary science leading to safer and sustainable life£¨¶¾Àíѧ--ÒýÁì¸üÇå¾²ºÍ¿ÉÒ»Á¬µÄ¶àѧ¿Æ¿ÆÑ§£© ¡£º­¸ÇÏÖ´ú¶¾ÀíѧµÄ¶à½Ç¶ÈÒéÌ⣬²¢»ùÓÚ¶¾ÀíѧµÄÆÕ±éÐԺͿçѧ¿ÆÏàÖúµÄÖ÷ÒªÐÔ£¬Õö¿ª·ÖÏíºÍ×êÑÐ ¡£

ÈÕÆÚ | 2023Äê9ÔÂ10-13ÈÕ

ËùÔÚ | ¬²¼¶ûÑÅÄÇ£¬Ë¹ÂåÎÄÄáÑÇ

×ðÁú¿­Ê±Õ¹Ì¨ |#45

EUROTOX 2023 »áºó¾«Ñ¡ ×ðÁú¿­Ê±ÍŶÓÓëÄú¹²¾Û¶¾Àíѧ´ó»á-1.jpg

EUROTOX 2023 »áºó¾«Ñ¡ ×ðÁú¿­Ê±ÍŶÓÓëÄú¹²¾Û¶¾Àíѧ´ó»á-3.jpg

EUROTOX 2023 ÒéÌ⾫ѡ

Ò©ÎïµÄ¶¾ÐÔÆÀ¹ÀÊÇÒ©Î↑·¢Àú³ÌÖкÜÊÇÖ÷ÒªµÄÒ»»· ¡£Ëæ×ÅÊÖÒÕǰ½ø£¬Ñо¿Ö°Ô±ÉîÈë¶¾Àí»úÖÆ£¬Ò»Ö±¸ÄÉÆ¶¾ÀíѧÑо¿ÖеÄй¤¾ßºÍÕ½ÂÔ£¬ÒÔïÔÌ­Ò©Î↑·¢ÖÐÓëÇå¾²Ïà¹ØµÄÏûºÄ ¡£¶¾ÀíѧÔÚÁÙ´²Ç°µÄÄ¿µÄÒ²²»ÔÙÊǼòÆÓµÄ¡°Ç°¸ººÉ¡±ÏûºÄ£¬»¹½«Äܹ»¼õÇáÒ©Î︱×÷Ó㬿ª·¢¸üÇå¾²µÄÉúÎï±ê¼ÇÎïÄÉÈëÑо¿¹æÄ££¬´Ó¶øÎªÒ©ÎïÁÙ´²ÀÖ³ÉÔöÌíÒ»·Ý¿ÉÄÜÐÔ ¡£

´Ë´Î´ó»á°²ÅÅÁËһϵÁо«²ÊµÄѧÊõÄÚÈÝ£¬×ðÁú¿­Ê±¾«Ñ¡ÁËÖØµã±¨¸æÐÅÏ¢£¬¹©Äú²Î¿¼ ¡£

±¨¸æ£ºLecture Award: Opioid-related toxicity: from respiratory depression to the overdose epidemic

°¢Æ¬ÀàÒ©ÎïÏà¹Ø¶¾ÐÔ£º´ÓºôÎüÒÖÖÆµ½ÓÃÒ©¹ýÁ¿Ê¢Ðв¡

½²ÕߣºBruno M¨¦garbane (FR)

ʱ¼ä£ºMonday, 11 September£¬08h30 ¨C 09h30

±ç˵£ºDebate: Will the exposome drastically change the practice of toxicology?

̻¶×é»á³¹µ×¸Ä±ä¶¾Àíѧʵ¼ùÂð£¿

EUROTOX±çÊÖ: Robert Barouki (Universit¨¦ de Paris, FR)

SOT±çÊÖ: Robert Wright (Icahn School of Medicine at Mount Sinai, NY, US)

ʱ¼ä£ºMonday, 11 September£¬13h00 ¨C 14h00

±¨¸æ£ºMerit Award Lecture: Mechanisms Matter: Deriving Causal Concepts to Informing Risk Assessment

»úÖÆµÄÖ÷ÒªÐÔ£º µ¼ÏòÒò¹û¿´·¨£¬ÌṩΣº¦ÆÀ¹ÀÒÀ¾Ý

½²ÕߣºLois D. Lehman-McKeeman (Bristol Myers Squibb, NJ, US)

ʱ¼ä£ºTuesday, 12 September£¬08h30 ¨C 09h30

±¨¸æ£ºHESI CITE Lecture£ºTranslational knowledge in minipigs: a way forward to reduce the use of non-human primates in non-clinical safety studies

ÃÔÄãÖíµÄת»¯ÖªÊ¶£ºïÔÌ­ÔÚ·ÇÁÙ´²Çå¾²ÐÔÑо¿ÖÐʹÓ÷ÇÈËÁ鳤ÀදÎïµÄ³ö·

½²ÕߣºSteven van Cruchten (University of Antwerp, BE)

ʱ¼ä£ºTuesday, 12 September£¬13h00 ¨C 14h00

ÆäËû¾«²ÊÂÛ̳

11 September

S01: Human biomonitoring ¨C a view to the future based on current achievements

ÈËÀàÉúÎï¼à²â--»ùÓÚÏÖÓÐÏ£ÍûµÄδÀ´Õ¹Íû

S03: Current and future perspectives on the extended one-generation reproductive toxicity study (EOGRTS)

ÑÓÉìÒ»´úÉúÖ³¶¾ÐÔ¼ì²â£¨EOGRTS£©µÄÄ¿½ñÇéÐÎÓëδÀ´Õ¹Íû

S05: Consideration of the endogenous exposome in risk assessment

Σº¦ÆÀ¹ÀÖжÔÄÚÔ´ÐÔ̻¶ÌåÒòËØµÄ˼Á¿

S07: Involvement of mitochondria in adverse drug reactions

ÏßÁ£Ìå¼ÓÈëÒ©Îï²»Á¼·´Ó¦

S09: Current use of NAMS/alternatives in DART testing

ÏÖÔÚÔÚ DART ²âÊÔÖÐʹÓõÄNAMS/Ìæ»»ÒªÁì

S11: Contact allergen potency: the missing piece in the huge puzzle of alternative methods

½Ó´¥¹ýÃôԭЧÁ¦£ºÌæ»»ÒªÁìµÄ¾ÞºÆ½ÙÌâÖÐȱʧµÄÒ»»·

S12: Finding synergies for 3Rs ¨C toxicokinetics, physiologically-based kinetic (PBK) models and read-across

ѰÕÒ 3R µÄЭͬ×÷ÓÃ--¶¾´ú¶¯Á¦Ñ§¡¢»ùÓÚÐÄÀíѧµÄ¶¯Á¦Ñ§ (PBK) Ä£×ӺͶÁÊý½»Ö¯

12 September

S13: Acceptance and use of in vitro methods: a perspective from various chemical sectors

ÌåÍâÒªÁìµÄÓ¦ÓãºÀ´×Ô²î±ð»¯Ñ§ÁìÓòµÄÊÓ½Ç

S14: NAM mechanistic information for the risk assessment of chemical mixtures

ÓÃÓÚ»¯Ñ§»ìÏýÎïΣº¦ÆÀ¹ÀµÄNAM»úÀíÐÅÏ¢

S15: Next generation risk assessment of food chemicals, environmental contaminants and pharmaceuticals using open-source modelling platforms: perspectives from regulatory agencies, academia and industry

ʹÓÿªÔ´½¨Ä£Æ½Ì¨¶ÔʳÎﻯѧƷ¡¢ÇéÐÎÎÛȾÎïºÍÒ©Æ·¾ÙÐÐÏÂÒ»´úΣº¦ÆÀ¹À£ºÀ´×Ôî¿Ïµ»ú¹¹¡¢Ñ§Êõ½çºÍ¹¤Òµ½çµÄ¿´·¨

S16: Organ-on-a-chip and the developing role in early drug development

Æ÷¹ÙоƬºÍÔÚÔçÆÚÒ©Î↑·¢ÖÐʩչµÄ×÷ÓÃ

S17: Critical organs and exposure windows for developmental immunotoxicity assessment

·¢ÓýÆÚÃâÒß¶¾ÐÔÆÀ¹ÀµÄÒªº¦Æ÷¹ÙºÍ̻¶´°¿Ú

S20: Are diseases and conditions related to hormone imbalance really increasing?

ÓëºÉ¶ûÃÉʧµ÷Óйصļ²²¡ºÍ²¡Ö¢ÕæµÄÔÚÔöÌíÂð£¿

S21: Environmental chemical mixtures and cancer hallmarks ¨C new developments and open questions

ÇéÐλ¯Ñ§»ìÏýÎïºÍ°©Ö¢±ê¼Ç--ÐÂÏ£ÍûºÍδ¾öÎÊÌâ

S22: Role of immunity and contribution of immunotoxicity in the identification of non-genotoxic carcinogens

ÃâÒßµÄ×÷ÓúÍÃâÒß¶¾ÐÔÔÚÈ·¶¨·ÇÒÅ´«¶¾ÐÔÖ°©ÎïÖеÄТ˳

ÍÆ¼öÔĶÁ

×ðÁú¿­Ê±¶¾ÀíÑо¿Ð§ÀÍÆ½Ì¨

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿